Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy (chemotherapy or abiraterone)?-a report of three cases.

Mohan Hingorani, Sanjay Dixit, Pattu Pugazhenthi, Simon Hawkyard, Andrew Robertson, Richard Khafagy

Open access · greenAbstract readCase Reports

In one paragraph

Article in Cancer biology & medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.2field-weighted citation impact, top 40% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution.European journal of nuclear medicine and molecular imaging · 2016
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mohan Hingorani1 Department of Clinical Oncology, Castle Hill Hospital, Hull and East Yorkshire, NHS Trust, Cottingham, East Riding of Yorkshire, HU16 5JQ, UK ; 2 Department of Urology, Scarborough District General Hospital, Scarborough ON M1P 2V5, UK.

Sanjay Dixit1 Department of Clinical Oncology, Castle Hill Hospital, Hull and East Yorkshire, NHS Trust, Cottingham, East Riding of Yorkshire, HU16 5JQ, UK ; 2 Department of Urology, Scarborough District General Hospital, Scarborough ON M1P 2V5, UK.

Pattu Pugazhenthi1 Department of Clinical Oncology, Castle Hill Hospital, Hull and East Yorkshire, NHS Trust, Cottingham, East Riding of Yorkshire, HU16 5JQ, UK ; 2 Department of Urology, Scarborough District General Hospital, Scarborough ON M1P 2V5, UK.

Simon Hawkyard1 Department of Clinical Oncology, Castle Hill Hospital, Hull and East Yorkshire, NHS Trust, Cottingham, East Riding of Yorkshire, HU16 5JQ, UK ; 2 Department of Urology, Scarborough District General Hospital, Scarborough ON M1P 2V5, UK.

Andrew Robertson1 Department of Clinical Oncology, Castle Hill Hospital, Hull and East Yorkshire, NHS Trust, Cottingham, East Riding of Yorkshire, HU16 5JQ, UK ; 2 Department of Urology, Scarborough District General Hospital, Scarborough ON M1P 2V5, UK.

Richard Khafagy1 Department of Clinical Oncology, Castle Hill Hospital, Hull and East Yorkshire, NHS Trust, Cottingham, East Riding of Yorkshire, HU16 5JQ, UK ; 2 Department of Urology, Scarborough District General Hospital, Scarborough ON M1P 2V5, UK.

Hull and East Yorkshire Hospitals NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Palliative radiotherapy (pRT) is primarily employed for palliation of bone pain in patients with castrate-resistant prostate cancer (CRPC). However, evidence that pRT influences prostate-specific antigen response in patients with CRPC on systemic therapy is lacking. We describe three cases of CRPC progressing after treatment with docetaxel (n=2) and abiraterone (n=1), who responded unusually after pRT for bone pain with the development of a significant biochemical response and restoration of response to systemic therapy. The possibility of pRT influencing metastatic disease in CRPC has not been previously reported, and raises the possibility of radiation-induced modulation of anti-tumor immune response mechanisms that may play a role in the restoration of response to systemic treatment.

Indexed as

chemotherapypalliativeProstate cancerradiotherapy

Identifiers

PMID25859413

DOI10.7497/j.issn.2095-3941.2014.0025

PMCPMC4383847

OpenAlexW1546949546

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.